Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

Roy Fleischmann, Wassim Saikali, Sharad Lakhanpal, Daniel F. Alvarez, Donna S. Cox, Claudia Ana Ianos, Wuyan Zhang, Carol Cronenberger, Karen Wang